Needham & Company
View Older Stories
-
UPDATE: Needham & Company Upgrades Chelsea Therapeutics (CHTP) to Buy
-
Needham & Company Maintains a 'Hold' on Chelsea Therapeutics (CHTP); Need More Clarity
-
Needham & Company Downgrades Chelsea Therapeutics (CHTP) to Hold; Receives Complete Response Letter for Northera
-
Traders Eye Chelsea Therapeutics (CHTP) Ahead of Northera PDUFA Date
-
Needham & Company Reiterates a 'Buy' on Chelsea Therapeutics (CHTP); Q4 Review: Northera PDUFA Date Approaching
-
Needham & Company Reiterates a 'Buy' on Chelsea Therapeutics (CHTP); FDA Votes in Favor of Northera
-
Chelsea Therapeutics (CHTP) Plans to Offer $20 Million in Common Stock
-
Needham & Company Reiterates a 'Buy' on Chelsea Therapeutics (CHTP); Interim CH-4051 Data in RA Consistent with Safety/Efficacy Benefits Over Methotrexate
-
Needham & Company Maintains a 'Buy' on Chelsea Therapeutics (CHTP); Overall Undervalued
-
Needham & Company Reiterates a 'Buy' on Chelsea Therapeutics (CHTP); 2Q11 Review: Northera NDA Submission Expected Later this Quarter
-
Needham & Company Reiterates a 'Buy' on Chelsea Therapeutics (CHTP); Q1 Review; Northera NDA Submission May Offer Upside in Q3
-
Needham & Company Reiterates a 'Buy' on Chelsea Therapeutics (CHTP); Northera NDA Submission on Track for 3Q11
-
Needham & Company Reiterates a 'Buy' on Chelsea Therapeutics (CHTP); Option Strategy
-
Needham & Company reiterates a 'Buy' on Chelsea Therapeutics (CHTP); Regulatory Timelines Accelerated, But Believe Positive Study 306 Outcome May Still Be Needed for Approval
-
Needham & Company Reiterates a 'Buy' on Chelsea Therapeutics (CHTP); Droxidopa Programs Remain on Track
-
Chelsea Therapeutics (CHTP) Announces $35M Common Offering
-
Needham & Company reiterates a 'Buy' rating on Chelsea Therapeutics (CHTP); Droxidopa Study 301 Meets Primary Endpoint
-
Needham & Company Reiterates a 'Buy' on Chelsea Therapeutics (CHTP); Droxidopa Study 301 Meets Primary Endpoint, an Important Milestone
-
Unusual 11 Mid-Day Movers 08/10: RMX, AAU, ZSTN, HOOK, QNST, CHTP Higher; CYRX, SCLN, HQS, ABK, CVBF Lower
-
Needham & Company reiterates a 'Buy' on Chelsea Therapeutics (CHTP); Droxidopa Program Remains on Track, Shares Undervalued
-
Needham & Company Initiates Coverage on Chelsea Therapeutics (CHTP) with a Buy
-
Needham & Company Initiates Coverage of Chelsea Therapeutics (CHTP) with a Buy
-
Needham Starts Chelsea Therapeutics (CHTP) at Buy with $7 Price Target
-
Chelsea Therapeutics (CHTP) to Raise $18.2M in Offering of Stock and Warrants